Next Article in Journal
Deciphering Single Nucleotide Polymorphisms and Evolutionary Trends in Isolates of the Cydia pomonella granulovirus
Next Article in Special Issue
Roles of APOBEC3A and APOBEC3B in Human Papillomavirus Infection and Disease Progression
Previous Article in Journal
Reliable Detection of Herpes Simplex Virus Sequence Variation by High-Throughput Resequencing
Previous Article in Special Issue
Changing Stem Cell Dynamics during Papillomavirus Infection: Potential Roles for Cellular Plasticity in the Viral Lifecycle and Disease
Open AccessReview

Targeting Persistent Human Papillomavirus Infection

Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
Author to whom correspondence should be addressed.
Academic Editor: Alison A. McBride
Viruses 2017, 9(8), 229;
Received: 30 July 2017 / Revised: 30 July 2017 / Accepted: 15 August 2017 / Published: 18 August 2017
(This article belongs to the Special Issue Expert Views on HPV Infection)
While the majority of Human papillomavirus (HPV) infections are transient and cleared within a couple of years following exposure, 10–20% of infections persist latently, leading to disease progression and, ultimately, various forms of invasive cancer. Despite the clinical efficiency of recently developed multivalent prophylactic HPV vaccines, these preventive measures are not effective against pre-existing infection. Additionally, considering that the burden associated with HPV is greatest in regions with limited access to preventative vaccination, the development of effective therapies targeting persistent infection remains imperative. This review discusses not only the mechanisms underlying persistent HPV infection, but also the promise of immunomodulatory therapeutic vaccines and small-molecular inhibitors, which aim to augment the host immune response against the viral infection as well as obstruct critical viral–host interactions. View Full-Text
Keywords: HPV; persistent infection; cervical cancer; therapeutics; vaccines; episome maintenance; E2 protein HPV; persistent infection; cervical cancer; therapeutics; vaccines; episome maintenance; E2 protein
Show Figures

Graphical abstract

MDPI and ACS Style

Shanmugasundaram, S.; You, J. Targeting Persistent Human Papillomavirus Infection. Viruses 2017, 9, 229.

AMA Style

Shanmugasundaram S, You J. Targeting Persistent Human Papillomavirus Infection. Viruses. 2017; 9(8):229.

Chicago/Turabian Style

Shanmugasundaram, Srinidhi; You, Jianxin. 2017. "Targeting Persistent Human Papillomavirus Infection" Viruses 9, no. 8: 229.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Search more from Scilit
Back to TopTop